HIV Alert: Options for Integrase Inhibitor Therapy Following Recent Drug Approvals

Listen to downloadable audio from a series of live Webinars by Paul E. Sax, MD, and Brian Wood, MD, in which the use of recently approved integrase inhibitor–based regimens is discussed and audience questions on this subject are addressed.
Format: Audio (.mp3)
File Size: 8.37 MB
Released: April 23, 2018

Listen to downloadable audio from a series of live Webinars by Paul E. Sax, MD, and Brian Wood, MD, in which the use of recently approved integrase inhibitor–based regimens is discussed and audience questions on this subject are addressed. (~40 minutes)

Paul E. Sax, MD, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ ViiV, Janssen, and Merck and funds for research support from Bristol-Myers Squibb, Gilead Sciences, and GlaxoSmithKline/ViiV.

Brian Wood, MD, has no real or apparent conflicts of interest to report.

Acknowledgements

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grant provided by:
ViiV Healthcare

Related Content

Downloadable slideset from Clinical Care Options on with expert insight on emerging ART strategies, including rapid ART initiation and dual therapy.

Joseph J. Eron, Jr., MD
Program Director
Princy N. Kumar, MD, FIDSA, MACP
Program Director
Eric S. Daar, MD
Released: January 30, 2019

Commentary from David A. Wohl, MD, on latest HIV conference data behind virologically suppressed patients switching to new 2- and 3-drug combinations.

David A. Wohl, MD Released: January 23, 2019

Downloadable slideset covering key HIV studies presented at IDWeek, Comorbidities Workshop, and HIV Glasgow 2018, reported by Clinical Care Options

Babafemi Taiwo, MBBS Released: December 5, 2018

Study 1878: Suppression maintained through Week 48 after switch to BIC/FTC/TAF with M184V/I presented at Glasgow 2018 reported by Clinical Care Options

Released: November 30, 2018

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?